Effect of avian bursa of Fabricius extract on the compensatory potential of bone marrow, spleen, and thymus cells in cyclophosphamide-induced mice

Malignant neoplasms often arise under immunodeficiency conditions. However, anticancer chemotherapeutic drugs can also cause the development or aggravate immunodeficiency by affecting the bone marrow function. Previous studies have shown that the bioorganocomplex obtained from the chickens’ Fabricius bursa has an antioxidant and immunotropic effect. The aim of this research was to investigate the protective mechanism of the bioorganocomplex “Bursanatal” upon cyclophosphamide-induced immunosuppression in the bone marrow, thymus, spleen of C57Bl/6 mice. Immunodeficient state was induced with single cyclophosphamide injection (200 mg/kg). Histological, morphometric, radiological methods have been used, as well as immunohistochemical staining of the spleen and thymus with CD45 and CD3 antibodies. The studies showed that cyclophosphamide injection affects both peripheral blood and bone marrow. Moreover, neutrophilic, basophilic and erythroid precursor cells are less sensitive to the cyclophosphamide. Subsequently, on the 8 th day their compensatory hyperplasia has been observed. The use of mentioned bioorganocomplex was accompanied by increased counts of leukocytes, erythrocytes and hemoglobin in peripheral blood. Bone marrow cellularity also enriched, associated with active division and maturation of erythroid, myeloid, and lymphoid cells. Bioorganocomplex administration causes a significant decrease of the red pulp area in spleen of mice with cyclophosphamide-induced immunodeficiency. Activation of extramedullary hematopoiesis was found in spleen of treated mice, i.e., the number of colony-forming hematopoietic progenitors was increased. It was also noted that the reactive center areas in the white pulp were reduced, with a significant increase of CD3⁺ cell contents in red and white pulp under the “Bursanatal” treatment. At the same time, the preparation did not affect thymus pathomorphology.

1. Kolberg N.A., Tikhonova N.V., Tikhonov S.L., Leontieva S.A., Sergeeva I.Yu. Immunotropic Effect of Bursal Peptides on Mice with Experimental Immunodeficiency. Tekhnika i tekhnologiya pishchevykh proizvodstv = Food Processing: Techniques and Technology, 2022, Vol. 52, no. 2, pp. 296-309. (In Russ.)

2. Kohlberg N.A., Kohlberg M.A., Travnikova D.A., Danilova I.G., M ukhlynina E.A. Method of processing of Fabricia bursa of birds. Patent RU 2782347 C1, 26.10.2022.

3. Kolberg N.A., Mukhlynina E.A., Brilliant S.A., Danilova I.G., Gette I.F., Ulitko M.V. Immunotropic effect of the extract fabricia bursa broiler chickens on C57BL/6 and C57BL/10 mice with experimental immunodeficiency syndrome. APK Rossii = Agro-Industrial Complex of Russia, 2023, Vol. 30, no. 2, pp. 275-283. (In Russ.)

4. Kolberg N.A., Petrova O.G. Immune stimulants in poultry and livestock breeding. Ekaterinburg: Ural Publishing House, 2012. 195 с.

5. Nikityuk V.V. Blood and bone marrow. Chemotherapy in oncology. Standards of medical care: reference book/comp.: A.S. Dementyev, N.I. Zhuravleva, S.Yu. Kochetkov, E.Yu. Chepanova. Moscow: GEOTAR-Media, 2017, pp. 673-751.

6. Teles C.A., Medeiros-Souza P., Lima F.C., de Araújo B.G., Lima R.C. Use of cyclophosphamide in routine practice in the treatment of autoimmune rheumatic diseases. Nefrologiya = Nefrologiya, 2018, Vol. 22, no. 1, pp. 104-113. (In Russ.)

7. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, Vol. 68, no. 6, pp. 394-424.

8. Huang L., Shen M., Wu T., Yu Y., Yu Q., Chen Y., Xie J. Mesona chinensis Benth polysaccharides protect against oxidative stress and immunosuppression in cyclophosphamide-treated mice via MAPKs signal transduction pathways. Int. J. Biol. Macromol., 2020, Vol. 1, no. 152, pp. 766-774.

9. Panigrahy S.K., Jatawa S, Tiwari A. Therapeutic use of cyclophosphamide and its cytotoxic action. J. Pharm. Res., 2011, Vol. 4, no. 8, pp. 2755-2757.

10. Voelcke G. The Mechanism of action of cyclophosphamide and its consequences for the development of a new generation of oxazaphosphorine cytostatics. Sci. Pharm., 2020, Vol. 88, no. 4, 42. doi: 10.3390/scipharm88040042.

11. Zhu Q., Xu L.H. Analysis of related factors in myelosuppression by antitumor drugs. Pharm. Clin. Res., 2015, Vol. 23, pp. 68-70.